![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
,3
,**,,
* Department of Neurology, Harvard Medical School and the Beth Israel Deaconess Medical Center, Boston MA 02115;
Program in Neuroscience and
** Center for Neurodegeneration and Repair, Harvard Medical School and the Beth Israel Deaconess Medical Center, Boston MA 02115;
Department of Neurology and Neuroscience, Weil Medical College of Cornell University, New York, NY 10021;
Burke Medical Research Institute, White Plains, NY 10605; and
Department of Internal Medicine III, University of Cologne, 50924 Cologne, Germany
3To whom correspondence should be addressed. E-mail: plange{at}bidmc.harvard.edu.
In this review the current knowledge about the arginine-degrading enzyme arginase and its unexpected roles in survival and regeneration in the central nervous system will be discussed. Recent data suggest the neuroprotective effects of extracellularly applied arginase can be attributed to an activation of the endoplasmic reticulum stress response with a consequent change of the pro-survival gene expression profile. However, the activation of neural regeneration pathways caused by an upregulation of endogenous arginase I is mediated by polyamines, a group of arginase downstream products with widespread biological effects. In light of these new discoveries, there is heightened interest in the regulation of arginase I gene expression within the central nervous system. A number of transcription factors such as Sp1, C/EBP (CCATT/enhancer-binding protein), and CREB seem to be involved in the transcriptional control of arginase I and may contribute to the complex expression pattern of arginase I in distinct brain regions and during development. Beyond molecular mechanisms, this review will also include relevant clinical findings in patients with neurodegenerative diseases.
KEY WORDS: • arginase • arginine • neurodegeneration
This article has been cited by other articles:
|
|
 |
|
  D. Tonge, K. Chan, N. Zhu, A. Panjwani, M. Arno, S. Lynham, M. Ward, A. Snape, and J. Pizzey Enhancement of axonal regeneration by in vitro conditioning and its inhibition by cyclopentenone prostaglandins J. Cell Sci., August 1, 2008; 121(15): 2565 - 2577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Lange, J. C. Chavez, J. T. Pinto, G. Coppola, C.-W. Sun, T. M. Townes, D. H. Geschwind, and R. R. Ratan ATF4 is an oxidative stress-inducible, prodeath transcription factor in neurons in vitro and in vivo J. Exp. Med., May 12, 2008; 205(5): 1227 - 1242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Estevez, M. A. Sahawneh, P. S. Lange, N. Bae, M. Egea, and R. R. Ratan Arginase 1 Regulation of Nitric Oxide Production Is Key to Survival of Trophic Factor-Deprived Motor Neurons. J. Neurosci., August 15, 2006; 26(33): 8512 - 8516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Grasemann, F. Kurtz, and F. Ratjen Inhaled L-Arginine Improves Exhaled Nitric Oxide and Pulmonary Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 15, 2006; 174(2): 208 - 212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Grasemann, R. Schwiertz, S. Matthiesen, K. Racke, and F. Ratjen Increased Arginase Activity in Cystic Fibrosis Airways Am. J. Respir. Crit. Care Med., December 15, 2005; 172(12): 1523 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Morris Jr Enzymes of Arginine Metabolism J. Nutr., October 1, 2004; 134(10): 2743S - 2747S. [Abstract] [Full Text] [PDF]
|
|
